186 related articles for article (PubMed ID: 16954499)
1. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.
Moufarij MA; Sampath D; Keating MJ; Plunkett W
Blood; 2006 Dec; 108(13):4187-93. PubMed ID: 16954499
[TBL] [Abstract][Full Text] [Related]
2. Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.
Zecevic A; Sampath D; Ewald B; Chen R; Wierda W; Plunkett W
Clin Cancer Res; 2011 Jul; 17(14):4731-41. PubMed ID: 21632856
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
Pepper C; Lowe H; Fegan C; Thurieau C; Thurston DE; Hartley JA; Delavault P
Br J Cancer; 2007 Jul; 97(2):253-9. PubMed ID: 17579621
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine.
Huang P; Sandoval A; Van Den Neste E; Keating MJ; Plunkett W
Leukemia; 2000 Aug; 14(8):1405-13. PubMed ID: 10942236
[TBL] [Abstract][Full Text] [Related]
5. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.
Yamauchi T; Nowak BJ; Keating MJ; Plunkett W
Clin Cancer Res; 2001 Nov; 7(11):3580-9. PubMed ID: 11705880
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
Li L; Keating MJ; Plunkett W; Yang LY
Mol Pharmacol; 1997 Nov; 52(5):798-806. PubMed ID: 9351970
[TBL] [Abstract][Full Text] [Related]
7. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
Kaufman KL; Jenkins Y; Alomari M; Mirzaei M; Best OG; Pascovici D; Mactier S; Mulligan SP; Haynes PA; Christopherson RI
Oncotarget; 2015 Dec; 6(38):40981-97. PubMed ID: 26556860
[TBL] [Abstract][Full Text] [Related]
8. Targeting DNA repair with aphidicolin sensitizes primary chronic lymphocytic leukemia cells to purine analogs.
Starczewska E; Beyaert M; Michaux L; Vekemans MC; Saussoy P; Bol V; Arana Echarri A; Smal C; Van Den Neste E; Bontemps F
Oncotarget; 2016 Jun; 7(25):38367-38379. PubMed ID: 27223263
[TBL] [Abstract][Full Text] [Related]
9. Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes.
Adams DJ; Levesque MC; Weinberg JB; Smith KL; Flowers JL; Moore J; Colvin OM; Silber R
Leukemia; 2001 Dec; 15(12):1852-9. PubMed ID: 11753605
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro.
Li L; Liu X; Glassman AB; Keating MJ; Stros M; Plunkett W; Yang LY
Cancer Res; 1997 Apr; 57(8):1487-94. PubMed ID: 9108450
[TBL] [Abstract][Full Text] [Related]
11. Targeting base excision repair suggests a new therapeutic strategy of fludarabine for the treatment of chronic lymphocytic leukemia.
Bulgar AD; Snell M; Donze JR; Kirkland EB; Li L; Yang S; Xu Y; Gerson SL; Liu L
Leukemia; 2010 Oct; 24(10):1795-9. PubMed ID: 20811400
[No Abstract] [Full Text] [Related]
12. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.
Trachootham D; Zhang H; Zhang W; Feng L; Du M; Zhou Y; Chen Z; Pelicano H; Plunkett W; Wierda WG; Keating MJ; Huang P
Blood; 2008 Sep; 112(5):1912-22. PubMed ID: 18574029
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways.
Lozano-Santos C; Amigo-Jiménez I; Nova-Gurumeta S; Pérez-Sanz N; García-Pardo A; García-Marco JA
Biochem Biophys Res Commun; 2015 May; 461(2):243-8. PubMed ID: 25869069
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
Gandhi V; Kemena A; Keating MJ; Plunkett W
Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
[TBL] [Abstract][Full Text] [Related]
15. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
[TBL] [Abstract][Full Text] [Related]
16. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine.
Hewamana S; Lin TT; Jenkins C; Burnett AK; Jordan CT; Fegan C; Brennan P; Rowntree C; Pepper C
Clin Cancer Res; 2008 Dec; 14(24):8102-11. PubMed ID: 19088025
[TBL] [Abstract][Full Text] [Related]
17. Modulation of IL-4 level by fludarabine and its relation to apoptosis in chronic B-cell lymphocytic leukemia.
Shamaa LA; Hussein Ael-S; Balbaa OA; Farahat NM; Ali MA
Egypt J Immunol; 2008; 15(1):181-92. PubMed ID: 20306682
[TBL] [Abstract][Full Text] [Related]
18. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.
Moussay E; Palissot V; Vallar L; Poirel HA; Wenner T; El Khoury V; Aouali N; Van Moer K; Leners B; Bernardin F; Muller A; Cornillet-Lefebvre P; Delmer A; Duhem C; Ries F; van Dyck E; Berchem G
Mol Cancer; 2010 May; 9():115. PubMed ID: 20487546
[TBL] [Abstract][Full Text] [Related]
19. Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation.
Fu C; Shi X; Gong Y; Wan Y; Sun Z; Shi H; Wang Z; Marinaccio C; Crispino JD; Xu K
Cell Physiol Biochem; 2018; 50(6):2314-2328. PubMed ID: 30423551
[TBL] [Abstract][Full Text] [Related]
20. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.
Di Gaetano N; Xiao Y; Erba E; Bassan R; Rambaldi A; Golay J; Introna M
Br J Haematol; 2001 Sep; 114(4):800-9. PubMed ID: 11564066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
